ARK Invest carried out a concentrated portfolio reshuffle between March 25 and March 27, 2026, cutting roughly $84 million of exposure to large technology stocks and a Bitcoin ETF while redirecting capital toward healthcare AI and other disruptive themes. The trades point to a deliberate shift away from megacap winners and toward smaller positions that the firm appears to view as offering greater upside from current levels.
The most significant reductions were concentrated in a handful of well-known names. Meta Platforms was the largest single sale at about $45.6 million, followed by Nvidia at roughly $27.8 million, while ARK also trimmed around $11 million from its position in the ARK 21Shares Bitcoin ETF. The pace of activity accelerated on March 26, which stood out as the busiest selling day in the rebalancing window.
ARK Rotated Out of Strength and Reduced Exposure to Mature Leaders
Beyond Meta, Nvidia and ARKB, the firm also reduced positions across semiconductors, internet platforms and other established growth names. Notable trims included Advanced Micro Devices, Roku, Bullish, Deere & Co., Taiwan Semiconductor Manufacturing, Broadcom, Alphabet, Block, Archer Aviation and Recursion Pharmaceuticals. The broader pattern suggests ARK was not making isolated adjustments, but actively reducing exposure across segments where gains may already be more fully reflected in valuations.
That selling was matched by fresh buying in areas more closely tied to ARK’s higher-conviction disruptive themes. The firm added as much as $4.1 million in Tempus AI, lifting the healthcare AI company into the position of ARKK’s third-largest holding and reinforcing ARK’s preference for names it sees as mispriced under weak sentiment. The move fits with a more selective approach to AI, favoring specialized application layers over the most crowded megacap trades.
ARK also expanded positions in several other companies aligned with its long-term innovation thesis. The firm increased stakes in CRISPR Therapeutics, CoreWeave, Joby and MercadoLibre, shifting more capital toward biotechnology, AI infrastructure, aerospace and e-commerce. That combination shows a portfolio tilt toward businesses where adoption curves or technical milestones could still drive outsized re-rating potential.
The Rebalancing Also Changed ARK’s Digital Asset Positioning
The sales in ARKB were notable not only because of the amount involved, but because they came alongside a revision to ARK’s long-term Bitcoin outlook. As part of the broader portfolio update, the firm lowered its 2030 Bitcoin price target from $1.5 million to $1.2 million, describing the change as a pragmatic adjustment rather than a reversal of conviction. That suggests ARK remains constructive on digital assets, but is becoming more measured about the pace and scale of future upside.
Taken together, the transactions reflect a clear reallocation of risk rather than a defensive retreat. ARK appears to be moving capital out of positions where gains may be more fully priced in and into smaller, less liquid companies where execution and adoption could still drive sharper upside. That shift reduces some concentration in large-cap technology and semiconductors, but it also raises the portfolio’s exposure to company-specific risk.
ARK is rotating away from broad megacap exposure and toward narrower, higher-conviction bets in healthcare AI and other disruptive verticals, raising the performance bar for the new additions as they now need to justify the capital reallocation through tangible execution.